Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | THRA | P10827 | 6/20 | 0.34 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 6/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566123 | 0.91 | ATM (0.45) | ATMKMT2ATHRARAPGEF3RAPGEF4 | |
| SCHEMBL5567323 | 0.83 | THRA (0.47) | ATMKMT2ATHRATHRBNOTUM | |
| SCHEMBL10421411 | 0.82 | ATM (0.46) | ATMKMT2APDE2ATHRARAPGEF3 | |
| SCHEMBL6454982 | 0.82 | THRA (0.42) | ATMKMT2ATHRATHRBMEN1 | |
| SCHEMBL10419933 | 0.78 | THRA (0.45) | ATMKMT2ATHRATHRBMEN1 | |
| SCHEMBL5561375 | 0.78 | MEN1 (0.46) | KMT2ATHRATHRBMEN1 | |
| SCHEMBL10419977 | 0.75 | THRA (0.43) | ATMKMT2ATHRATHRBMEN1 | |
| SCHEMBL10672779 | 0.74 | THRA (0.44) | ATMKMT2ATHRATHRBNOTUM | |
| SCHEMBL10421476 | 0.71 | ATM (0.48) | ATMKMT2ATHRAMEN1GAA | |
| SCHEMBL5791574 | 0.71 | THRA (0.52) | ATMKMT2ATHRATHRBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951857-B2 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD | 2005-10-04 | — | — | US | disclosed |
| US-6743792-B2 | ANTIINFLAMMATORY AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-01 | — | — | US | disclosed |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | FREYNE EDDY JEAN EDGARD (BE) | 2003-11-27 | — | — | US | disclosed |
| US-20020042416-A1 | Antiinflammatory agents | FREYNE EDDY JEAN EDGARD (BE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042416-A1 | Antiinflammatory agents | CCR1, CCR6, FPR1 | ATM 4851/4885KMT2A 4147/4885PDE2A 956/4885 |
| US-20030220331-A1 | Interleukins; cytokines; for treating eosinophil-dependent inflammatory disease/bronchial asthma | IL6, CCR1, CCR6 | ATM 4769/4885KMT2A 3682/4885PDE2A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.